THERMO FISHER SCIENTIFIC Business Summary

Thermo Fisher Scientific Inc. (TMO) operates as a global leader in the life sciences industry, generating revenue through a diversified mix of product sales (instruments, reagents, and consumables) and high-margin service contracts, including clinical research and biopharma manufacturing. The company is organized into four primary segments: Life Sciences Solutions, which provides biological research tools; Analytical Instruments, focusing on chromatography and mass spectrometry; Specialty Diagnostics, offering clinical and immunodiagnostic solutions; and Laboratory Products and Biopharma Services, which encompasses its extensive contract research organization (CRO) and laboratory supply channels. As of February 2026, Thermo Fisher maintains a dominant market position by integrating research tools with end-to-end clinical services, effectively competing against major rivals such as Danaher Corporation, Agilent Technologies, Illumina, and Medpace. Its competitive advantage is anchored in its "PPI Business System" for operational excellence and a massive distribution network that serves over 400,000 customers across pharmaceutical, biotech, and academic sectors. Founded through the 2006 merger of Thermo Electron (est. 1956 by George Hatsopoulos and Peter Nomikos) and Fisher Scientific (est. 1902 by Chester Fisher), the company is currently led by Chairman, President, and CEO Marc N. Casper, a Harvard MBA and former Bain & Company consultant who has steered the firm since 2009. The executive team includes Senior VP and CFO Stephen Williamson and Chief Scientific Officer Karen E. Nelson. In a significant leadership transition announced in early 2026, Gianluca Pettiti (currently EVP) is slated to become President and COO on March 1, 2026, succeeding Michel Lagarde, while Michael Shafer assumes an expanded executive role reporting to the CEO. The company’s board of directors features prominent industry figures such as Lead Independent Director Scott M. Sperling (Co-CEO of Thomas H. Lee Partners) and Karen S. Lynch (former CEO of CVS Health), reflecting a high-pedigree governance structure supported by major institutional investors including Vanguard and BlackRock.